Nootropil Dosage/Direction for Use





Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Oral formulations: Piracetam may be taken with or without food. The film-coated tablets should be swallowed with liquid. It is recommended to take the daily dose in two to four sub-doses.
Parenteral formulations: When parenteral administration is needed (e.g. swallowing difficulties, unconsciousness) piracetam can be administered intravenously at the same recommended daily dose.
The solution for injection will be administered intravenously over several minutes.
The solution for infusion will be administered continuously at the recommended daily dose over a 24 hour period.
Route of Administration: Oral formulations: For oral use.
Parenteral formulations: For intravenous use.
Adults: The daily dosage should begin at 7.2 g, increasing by 4.8 g every three or four days up to a maximum of 24 g, in two or three divided doses. Treatment with other anti-myoclonic medicinal products should be maintained at the same dosage. Depending on the clinical benefit obtained, the dosage of other such medicinal products should be reduced, if possible.
Once started, treatment with piracetam should be continued for as long as the original cerebral disease persists. In patients with an acute episode, spontaneous evolution may occur over time and an attempt should be made every 6 months to decrease or discontinue the medicinal treatment. This should be done by reducing the dose of piracetam by 1.2 g every two days (every three or four days in the case of a Lance-Adams syndrome, in order to prevent the possibility of sudden relapse or withdrawal seizures).
Elderly: Adjustment of the dose is recommended in elderly patients with compromised renal function (see Precautions; Renal impairment as follows).
For long-term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed.
Renal impairment: The daily dose must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (Clcr) in ml/min is needed. The Clcr in ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula (see equation):

Click on icon to see table/diagram/image

(See table.)

Click on icon to see table/diagram/image

Hepatic impairment: No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of dose is recommended (see dose adjustment in Renal Impairment previously mentioned).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in